Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised EQT IX in connection with sale of shares in Beijer Ref AB (publ) (1)
Mandate

Vinge has advised EQT IX in connection with sale of shares in Beijer Ref AB (publ)

September 18, 2024 Capital Markets and Public M&A

Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 17 September 2024.

In total, 20 million shares were placed at a price of SEK 165 per share, corresponding to a total value of SEK 3.3 billion.

Vinge’s team consisted of Sofie Bjärtun and Linnéa Sellström.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026